Genelux Corp GNLX
We take great care to ensure that the data presented and summarized in this overview for GENELUX CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in GNLX
Top Purchases
Top Sells
About GNLX
Insider Transactions at GNLX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 01
2025
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+12.35%
|
-
|
|
Aug 27
2025
|
Joseph Cappello Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
107,500
+40.22%
|
-
|
|
Aug 27
2025
|
James L Tyree Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,283
+24.66%
|
-
|
|
Aug 27
2025
|
Mary Mirabelli Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,283
+23.32%
|
-
|
|
Aug 27
2025
|
Tony Yu SVP, Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
101,480
+40.35%
|
-
|
|
Aug 27
2025
|
John W Smither Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,283
+22.91%
|
-
|
|
Aug 27
2025
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
26,230
+30.07%
|
-
|
|
Aug 27
2025
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
361,200
+39.46%
|
-
|
|
Aug 27
2025
|
John Thomas Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,283
+4.24%
|
-
|
|
Jun 06
2025
|
John Thomas Director |
SELL
Bona fide gift
|
Direct |
25,000
-4.95%
|
-
|
|
May 12
2025
|
Ralph Smalling Head of Regulatory |
SELL
Open market or private sale
|
Direct |
1,259
-3.5%
|
$2,518
$2.92 P/Share
|
|
May 12
2025
|
Joseph Cappello Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
4,737
-8.31%
|
$9,474
$2.92 P/Share
|
|
May 12
2025
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
5,579
-10.48%
|
$11,158
$2.92 P/Share
|
|
May 12
2025
|
Thomas Zindrick President and CEO |
SELL
Open market or private sale
|
Direct |
10,764
-5.32%
|
$21,528
$2.92 P/Share
|
|
May 12
2025
|
Sean Ryder General Counsel |
SELL
Open market or private sale
|
Direct |
4,475
-8.59%
|
$8,950
$2.92 P/Share
|
|
Mar 14
2025
|
Sean Ryder General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
10,708
+17.05%
|
-
|
|
Mar 14
2025
|
Tony Yu SVP, Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
13,350
+20.05%
|
-
|
|
Mar 14
2025
|
Joseph Cappello Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,350
+18.98%
|
-
|
|
Mar 14
2025
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
4,172
+10.38%
|
-
|
|
Mar 14
2025
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
30,339
+13.05%
|
-
|
Last 12 Months Summary
Buy / Acquisition
1.04M
Shares
From
10
Insiders
| Grant, award, or other acquisition | 1.04M shares |
|---|
Sell / Disposition
222K
Shares
From
9
Insiders
| Open market or private sale | 197K shares |
|---|---|
| Bona fide gift | 25K shares |